Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.

Khanh Tu Do,John L. Hays,Stephen V. Liu,Alice P. Chen,Geraldine O'Sullivan,Jeffrey G. Supko,Kristin Beebe,Len Neckers,Jane B. Trepel,Min-Jung Lee,Courtney Gannon,Alona Muzikansky,Susana M. Campos,Elizabeth Downey,Andrew Wolanski,Jennifer Hedglin,Fernanda I. Arnaldez,James H. Doroshow,Geoffrey I. Shapiro

Phase I trial of the combination of the heat shock protein-90 inhibitor onalespib (AT13387) and the cyclin-dependent kinase inhibitor AT7519M in patients with advanced solid tumors.

2019

Khanh Tu Do
John L. Hays
Stephen V. Liu
Alice P. Chen
Geraldine O'Sullivan
Jeffrey G. Supko
Kristin Beebe
Len Neckers
Jane B. Trepel
Min-Jung Lee
Courtney Gannon
Alona Muzikansky
Susana M. Campos
Elizabeth Downey
Andrew Wolanski
Jennifer Hedglin
Fernanda I. Arnaldez
James H. Doroshow
Geoffrey I. Shapiro

2619Background: The 90kDa heat shock protein (HSP90) participates in the folding, stabilization, activation, and proteolytic turnover of aberrant proteins that contribute to the growth and survival...

Keywords:

Heat shock protein
Cyclin-dependent kinase
Pathology
Cancer research
Medicine
Hsp90
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations